Janssen new drugs?

19
Myrl Roob asked a question: Janssen new drugs?
Asked By: Myrl Roob
Date created: Sat, Feb 20, 2021 5:16 AM
Date updated: Wed, Oct 19, 2022 9:37 PM

Content

Top best answers to the question «Janssen new drugs»

TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen's long-acting ...

18 other answers

TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human ...

RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO ® (rivaroxaban) in patients with peripheral artery disease (PAD).

Affording and Accessing Our Medicines. We are committed to helping patients find the resources they need to start and stay on their Janssen medicines during the COVID-19 pandemic. Visit Janssen CarePath to learn how we’re continuing to help patients in the U.S. afford and access our medicines.

Janssen R&D Ireland has signed a licensing agreement with PATH for the early development of a long-acting depot formulation of the human immunodeficiency virus type 1 (HIV-1) drug rilpivirine. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is being developed as potential pre-exposure prophylaxis against HIV infection

Potential new antimalarial drug candidates are being developed through an extended drug-discovery collaboration between Australian medical research institute WEHI and Janssen Pharmaceutica NV.

Janssen United States. > Products. Janssen has the following prescription pharmaceutical products in the United States. This information is intended for use by our customers, patients and healthcare professionals in the United States only.

Janssen’s lung cancer drug gets FDA breakthrough status 11 Mar 2020 (Last Updated March 11th, 2020 10:12) Janssen Pharmaceutical has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for JNJ-61186372 (JNJ-6372) to treat metastatic non-small cell lung cancer (NSCLC).

A single-dose Covid vaccine made by Janssen has been approved for use in the UK by the medicines regulator. The vaccine was 85% effective in stopping severe illness from Covid-19 in trials and has ...

The drug, amivantamab, is a treatment for non-small cell lung cancer (NSCLC). The FDA decision Friday covers adults whose disease is characterized by an exon 20 insertion mutation to epidermal ...

TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir).

Affording and Accessing Our Medicines. We are committed to helping patients find the resources they need to start and stay on their Janssen medicines during the COVID-19 pandemic. Visit Janssen CarePath to learn how we’re continuing to help patients in the U.S. afford and access our medicines.

RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO ® (rivaroxaban) in patients with peripheral artery disease (PAD).

Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.

Janssen R&D Ireland has signed a licensing agreement with PATH for the early development of a long-acting depot formulation of the human immunodeficiency virus type 1 (HIV-1) drug rilpivirine. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is being developed as potential pre-exposure prophylaxis against HIV infection

Johnson & Johnson has handed in its New Drug Application for its multiple sclerosis (MS) hopeful as it hopes to get in on this blockbuster market. The therapy, ponesimod, is an S1P1 ...

Janssen’s lung cancer drug gets FDA breakthrough status 11 Mar 2020 (Last Updated March 11th, 2020 10:12) Janssen Pharmaceutical has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for JNJ-61186372 (JNJ-6372) to treat metastatic non-small cell lung cancer (NSCLC).

March 6, 2019. The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be ...

Janssen. Pharmaceutical Companies of Johnson & Johnson. Johnson & Johnson Innovation. Johnson & Johnson Innovation. Advancing New Healthcare Solutions Through Collaboration. Johnson & Johnson Medical Devices Companies. Johnson & Johnson Medical Devices Companies. Reimagining the Way Healthcare Is Delivered. Our Consumer Safety and Care Commitment.

Your Answer